Fig. 4: Study design and efficacy of anti-hTfR1 antibody treatment in JUNV-infected hTfR1 mice (Trial 1). | Nature Communications

Fig. 4: Study design and efficacy of anti-hTfR1 antibody treatment in JUNV-infected hTfR1 mice (Trial 1).

From: Host receptor-targeted therapeutic approach to counter pathogenic New World mammarenavirus infections

Fig. 4

a Experimental design, (b) survival outcomes (n = 8 mice/treatment group and n = 3 untreated sham-infected controls), (c) percent change in body weight represented as a group mean ± standard error of the surviving animals compared to their starting weights on the day of infection and (d) clinical disease scores of surviving animals represented as group mean ± standard error during the course of the experiment. aLog-rank Mantel-Cox test. Antibody (Ab); Undefined: >50% survival. Source data are included in the Source Data file.

Back to article page